Overview

A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers

Status:
Not yet recruiting
Trial end date:
2025-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with tislelizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals